2 AI Stocks That Aren't Worth the Hype
Artificial intelligence (AI) stocks have been hot buys this year, but not all of them make for good long-term investments. Just about every business is trying to get in on the hype and launching AI-powered products and services, which can make it difficult to determine what's a good buy and what's not.
There are a couple of particularly risky stocks that AI investors have been gravitating toward this year that you're better off avoiding. Recursion Pharmaceuticals (NASDAQ: RXRX) and C3.ai (NYSE: AI) benefited from AI-related developments and news this year, but they have already started to give back some of those gains. And more losses could be on the way.
Biotech company Recursion Pharmaceuticals wasn't on many investors' radars for much of this year. But then came an announcement in July that changed all of that. News that tech giant Nvidia, which has become synonymous with AI hardware this year, was investing $50 million into Recursion was game-changing news for the healthcare stock.
Source Fool.com
